

## 1. General Information

<b>Cohort ID</b>	5002_14
<b>Title (Study Name)</b>	Placenta & Cord Blood Collection
<b>Principal investigator</b>	Prof. <sup>in</sup> Mila Cervar-Zivkovic
<b>Contact information</b>	<a href="mailto:pm-biobank@medunigraz.at">pm-biobank@medunigraz.at</a>
<b>Funding agency</b>	-----

## 2. Description

Fresh frozen placental tissue, umbilical cord blood (venous and arterial) as well as maternal blood samples have been collected from pregnant women at the time of delivery.

The sample donors comprise a control group as well as a group with pregnancy disorders, such as diabetes, IUGR or preeclampsia, as well as preterm delivery (see inclusion criteria).

The sample collection at the Department of Obstetrics and Gynecology followed a standard operating procedure (SOP). => Details in section 5.

## 3. Details

<b>ICD 10/O codes / Healthy</b>	-----	
<b>Key words</b>	placenta, umbilical cord blood, biomarkers, pregnancy disorders	
<b>Collection / Cohort size</b> 12/2022	1.489 aliquots collected from 143 women	
<b>Informed Consent (IC)</b>	<input checked="" type="checkbox"/> Broad Biobank IC <input type="checkbox"/> Specific Study IC	
<b>Status</b>	<input type="checkbox"/> In progress / compl. date: <input checked="" type="checkbox"/> Completed	
<b>Inclusion criteria</b>	<b>Age distribution</b>	women of childbearing age
	<b>Sex distribution (f:m)</b>	100% female
	<b>Others</b>	<ul style="list-style-type: none"> <li>➤ Cervical insufficiency without signs of inflammation and infection</li> <li>➤ Therapy refractory contractions - Activity without signs of inflammation</li> <li>➤ Placenta <math>\geq 37+0</math> SSW</li> <li>➤ Diabetes (DM I, DM II, GDM)</li> <li>➤ IUGR &lt; 5%</li> <li>➤ Premature birth <math>\leq 34 + 0</math> SSW</li> <li>➤ Preeclampsia, eclampsia, HELLP syndrome, graft preeclampsia</li> <li>➤ Hypertension</li> </ul> Control group (normal pregnancies)
<b>Earliest access</b>	As of now	
<b>Quality-standards</b>	<input checked="" type="checkbox"/> ISO 9001:2015 (SOPs)	
<b>Associated publications / references</b>	-----	



#### 4. Material available (aliquot size) and storage conditions

<b>Material</b>	<input checked="" type="checkbox"/> Serum (235 µl, 580 µl)	<input checked="" type="checkbox"/> -80°C	<input type="checkbox"/> liq. N <sub>2</sub>
	<input checked="" type="checkbox"/> EDTA plasma (580 µl) (arterial and venous cord blood)	<input checked="" type="checkbox"/> -80°C	<input type="checkbox"/> liq. N <sub>2</sub>
	<input checked="" type="checkbox"/> EDTA Buffy coat (300 µl)	<input checked="" type="checkbox"/> -80°C	<input type="checkbox"/> liq. N <sub>2</sub>
	<input type="checkbox"/> Snap frozen placental tissue	<input type="checkbox"/> -80°C	<input checked="" type="checkbox"/> liq. N <sub>2</sub>

#### 5. Additional Information

##### Tissue Collection

→ Placenta tissue samples were collected from 4 localizations (Q1 – Q4) according to the scheme below. For each localization, both fetal and maternal sides of placenta were collected in cryo tubes.



##### Blood Collection

→ Blood collection from the mother at the time of birth.

→ Collection of both arterial and venous umbilical cord blood from the placenta.

**Dokument erstellt** (tt/mm/yyyy):  
22/04/2021

**Letzte inhaltliche Aktualisierung** (tt/mm/yyyy):  
02/08/2023